Supplementary Table 1. Recanalization rate of NWS therapy and control group in stratified analysis

|  |  |  |  |
| --- | --- | --- | --- |
|  | NWS therapy group, n (%) | Control group, n (%) | *P* value |
| one vein with thrombosis | 6(42.9) | 5(26.3) | 0.459 |
| ＞one veins with thrombosis | 14(77.8) | 6(46.2) | 0.128 |

Supplementary Table 2. Conditional independence test

|  |  |  |  |
| --- | --- | --- | --- |
|  | Chi-square value | degree of freedom | *P* value |
| Cochran | 3.933 | 1 | 0.047 |
| Mantel-Haenszel | 2.855 | 1 | 0.091 |

Supplementary Table 3. Risk of bleeding of NWS therapy and control group

NWS therapy, nadroparin calcium-warfarin sequential therapy.

|  |  |  |  |
| --- | --- | --- | --- |
|  | NWS therapy group | Control group | *P* value |
| hematemesis | 1(3.13%) | 0 | 1.000 |
| melena | 0 | 0 | - |
| epistaxis | 0 | 0 | - |
| Injection site hemorrhage | 0 | 0 | - |